ISPOR - HPR38 Review of NICE, PBAC, and CDA HTA Outcomes For Oncology Drugs Approved by the FDA Through Project Orbis (2022-2023)

Full Text

HPR38 Review of NICE, PBAC, and CDA HTA Outcomes For Oncology Drugs Approved by the FDA Through Project Orbis (2022-2023)

Abstract

Authors

Apoorva Bodke Catherine A. Dutton Michael Tang

Back to Volume 28, Supplemental Issue 6S1

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now